Heska : 2021 Heska Investor Presentation

HESKA CORPORATION

Investor Presentation

June 2021

Kevin Wilson Chief Executive Officer & President

01 FORWARD-LOOKING STATEMENT & SAFE HARBOR DISCLAIMER

This presentation contains statements about the Company's business prospects and estimates of the Company's financial results for future periods that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects", "may", "anticipates", "intends", "would", "will", "plans", "believes", "estimates", "projected", "should", and similar words and expressions. Our forward-looking statements include statements relating to, among other things, our future financial and operating results, future sales, sales split percentages, sales geography percentages, market share, and strategic goals, long-term financial model, revenue growth potential, new product launch and performance, and the anticipated benefits of the scil acquisition and other acquisitions. These statements are intended to provide management's expectation of future events as of the date of this webcast; are based on management's estimates, projections, beliefs and assumptions as of the date of this webcast; and are not guarantees of future performance. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among other things, the adverse impact, and the duration, of the effects of the ongoing COVID-19 pandemic on consumer demand, our global supply chain and our business, results of operations, liquidity, financial condition and stock price, the ability to achieve the anticipated benefits of the scil acquisition and other acquisitions; supplier availability, competing suppliers, any product's ability to perform and be recognized as anticipated, in particular when such product is under development; Heska's ability to sell and market its products in an economically sustainable fashion, including related to varying customs, cultures, languages and sales cycles and uncertainties with foreign political and economic climates; the Company's ability to integrate the acquired scil business within its existing operations; and new product development and release schedules, as well as the other matters described under the headings "Business," "Risk Factors," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent quarterly reports on Form 10-Q for the period ended March 31, 2021, as well as those described from time to time in the Company's other filings with the U.S. Securities and Exchange Commission available at www.sec.gov. The Company specifically disclaims any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

2

01

02

03

04

05

HESKA INVESTOR PRESENTATION

Heska Strategic Role in Global Veterinary Health Market & Heska Strategic Plan

Double Customers & Geography Served

Double Product & Revenue Streams Served

Key Metrics & Considerations

Question & Answer

01 Heska Strategic Role in Global Veterinary Health Market & Heska Strategic Plan

01 Veterinary Healthcare

• Humanization of pets globally. "Pet families"
• Adoption rates at historic levels
• 10-14year juvenile, wellness and aging care
• Greater awareness of pet health and pet symptoms
• Historically recession resistant
• Positive regulatory, payor and demographic trends
• Accelerating industry investment and consolidation

Point of Care Diagnostics

• ~8%-10%Annual Global Veterinary Diagnostics Growth1
• Major veterinarian revenue / profit center in hospitals
• Diagnostics utilization is key
• Increases in hospital pet visits and POC utilization
• Favored by veterinarians (veterinary licensure required)
• New technologies and advancements pull tests to point of care
• Pricing tends to increase each year
• High priority spend; often first spend in tight budgets

Annual growth rate information derived from publicly available information data disclosed by third-party sources, our own internal estimates based on such data, and our knowledge of the industry; it has not been independently verified. Source: American Pet Prod Assoc Generational Report; 2017-18 Pet Owners' Survey; American Pet Products Association

1 Technavio Global Veterinary Diagnostics Market 2017-2021 report.

5